Skip to content
drillr.ai

NGNE

Neurogene Inc.

NASDAQ · USHealthcareBiotechnology
$37.34+0.08%

Price as of Jul 20, 2026

NGNE news

Neurogene Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company’s common stock to six new employees (the “Inducement Grants”) o

    Business Wire ·

  2. Neurogene Inc. Announces Proposed Public Offering

    Neurogene Inc. Announces Proposed Public Offering Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Neurogene expects to grant the underwriters a 30-day op

    Business Wire ·

  3. Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

    Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors Ms. Shafer, a proven commercial leader in rare neurological diseases, will lead Neurogene’s commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome Ms. Mikail, President and CFO of Neurogene, adds strategic and operational leadership to the Board as Company advances key priorities Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring li

    Business Wire ·

  4. Neurogene to Participate in Stifel 2026 Virtual CNS Forum

    Neurogene to Participate in Stifel 2026 Virtual CNS Forum Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum. Format: Management will participate in a fireside chat Date: Wednesday, March 18 at 9:00 a.m. ET A live webcast of the fireside chat will be accessible from the Investor Relatio

    Business Wire ·